Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms

References

• Luo Y, Zu Y, Ahmad S. Challenges of fixed dose combination product development. American Pharmaceutical Review 2007;10 (2): 120–126.
   Google Scholar
• Timmins P. (2006). Developing fixed combination drug products–Technical challenges and opportunities. In: The 10th Annual Drug Delivery Partnerships. Phoenix, AZ, USA.
   Google Scholar
• Pudipeddi M. (2010). Biopharmaceutical challenges in development of fixed-dose combinations. In: Eastern Pharmaceutical Technology Meeting. Somerset, New Jersey, USA.
   Google Scholar
• Karali TT. Available at: (http://www.pharmacircle.com/presentations/fixeddose.pdf)
   Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399–407.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527–533.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Henneckens CH. Aggrenox and aspirin in patients after ischemic stroke: the Aggrenox versus aspirin therapy evaluation trial. Eur J Pharmacol 2004;3:315–324.
   Google Scholar
• Easton J, Noble S, Perry CM, Cuffini AM, Jacobs MR, Subba Rao SD, Pichichero ME, Thornberry C. Amoxicillin/clavunic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs 2003;23:311–340.
   Google Scholar
• Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010;111:44–49.
   PubMed Web of Science ®Google Scholar
• Coleman JJ, Schuster CR, Dupont RL. Reducing the abuse potential of controlled substances. Pharmaceut Med 2010;24:21–36.
   Google Scholar
• World Health Organization Expert Committee. (2000). The use of essential drugs including the revised model list of essential drugs. Geneva.
   Google Scholar
• Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13 Suppl 1:S61–S72.
   Google Scholar
• Dublin CH. Combination products: strategies for continuous pipeline. Drug Deliv Tech 2005;5:41–46.
   Google Scholar
• Lacy CF, Armstrong LL, Goldman MP, Lance LL. (2006). Drug Information Handbook. 14th edition ed. Hudson, Ohio, USA: Lexi-Comp Inc.
   Google Scholar
• FDA Guidance for Industry. (2003). Estrogen/progestin drug products to treat vasomoto symptoms and vulvar vaginal atrophy symptoms recommendations for clinical evaluation. Rockville, MD, USA.
   Google Scholar
• FDA Guidance for Industry. (2006). Fixed Dose combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of HIV. Rockville, MD, USA.
   Google Scholar
• Guidance for Industry. (1999). Application covered by section 505b2, CDER, Editor. Rockville, MD.
   Google Scholar
• Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011;364:985–987.
   PubMed Web of Science ®Google Scholar
• FDA Guidance for Industry. (2010). Co-development of Two or More Unmarketed Investigational Drugs for Use in Combination. Rockville, MD, USA.
   Google Scholar
• World Health Organization Expert Committee. (2005). Fixed-dose combination medicinal products. Geneva, 94–142.
   Google Scholar
• Wechsler J. Combination products raise manufacturing challenges. Pharmaceut Tech 2005;29:32–40.
   Google Scholar
• Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M. Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull 2008;56:1455–1458.
   PubMed Web of Science ®Google Scholar
• Shiyani B, Gattani S, Surana S. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008;9:818–827.
   PubMed Web of Science ®Google Scholar
• Mandal U, Pal TK. Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm 2008;34:305–313.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm 2008;348:27–34.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Peppas NA, Bodmeier R. Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design. J Control Release 2000;69:455–468.
   PubMed Web of Science ®Google Scholar
• Benkerrour L, Galley O, Quinet F, Abebe A, Timmins P. Multilayered tablet containing pravastatin and aspirin and method, 2004, US patent, US2004/0115265.
   Google Scholar
• Podczeck F. Theoretical and experimental investigations into the delamination tendencies of bilayer tablets. Int J Pharm 2011;408:102–112.
   PubMed Web of Science ®Google Scholar
• Anuar MS, Briscoe BJ. Interfacial elastic relaxation during the ejection of bi-layered tablets. Int J Pharm 2010;387:42–47.
   PubMed Web of Science ®Google Scholar
• Tye CK, Sun CC, Amidon GE. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J Pharm Sci 2005;94:465–472.
   PubMed Web of Science ®Google Scholar
• Li SP, Karth MG, Feld KM, Di Paolo LC, Pendharkar CM, Williams RO. Evaluation of bilayer tablet machines–a case study. Drug Dev Ind Pharm 1995;21:571–590.
   Web of Science ®Google Scholar
• Wu CY, Jonathan P,Seville K. A comparative study of compaction properties of binary and bilayer tablets. Powder Tech 2009;189:285–294.
   Web of Science ®Google Scholar
• Inman SJ, Briscoe BJ, Pitt KG, Shiu C. The non-uniformity of microcrystalline cellulose bilayer tablets. Powder Tech 2009;188:283–294.
   Web of Science ®Google Scholar
• Inman SL, Briscoe BJ, Pitt KG, Shiu C. Topographic characterization of cellulose bilayered tablets interfaces. Chem Eng Res Des 2007;85:1005–1012.
   Google Scholar
• Akseli I, Dey D, Cetinkaya C. Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech 2010;11:90–102.
   PubMedGoogle Scholar
• Gandhi R, Lal Kaul C, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today 1999;4:160–170.
   PubMedGoogle Scholar
• Gainotti A, Bettini R, Gazzaniga A, Colombo P, Giordano F. Drug-β-cyclodextrin containing pellets prepared with a high-shear mixer. Drug Dev Ind Pharm 2004;30:1061–1068.
   PubMed Web of Science ®Google Scholar
• Mezreb N, Charrueau C, Boy P, Allain P, Chaumeil JC. Production of Carbopol 974P and Carbopol 971P pellets by extrusion-spheronization: optimization of the processing parameters and water content. Drug Dev Ind Pharm 2004;30:481–490.
   PubMed Web of Science ®Google Scholar
• Poelvoorde N, Huyghebaert N, Vervaet C, Remon JP. Optimisation of an enteric coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur J Pharm Biopharm 2008;69:969–976.
   PubMedGoogle Scholar
• Abdul S, Chandewar AV, Jaiswal SB. A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS). J Control Release 2010;147:2–16.
   PubMed Web of Science ®Google Scholar
• Kok PJAH, Von kP, Hoekzema MA, Kossen NWF. Development of particulate pulse-release formulation and their mathematical description. Powder Tech 2001;119:33–44.
   Web of Science ®Google Scholar
• Dashevsky A, Mohamad A. Development of pulsatile multiparticulate drug delivery system coated with aqueous dispersion Aquacoat ECD. Int J Pharm 2006;318:124–131.
   PubMed Web of Science ®Google Scholar
• Baki G, Bajdik J, Djuric D, Knop K, Kleinebudde P, Pintye-Hódi K. Role of surface free energy and spreading coefficient in the formulation of active agent-layered pellets. Eur J Pharm Biopharm 2010;74:324–331.
   PubMed Web of Science ®Google Scholar
• Cosijns A, Nizet D, Nikolakakis I, Vervaet C, De Beer T, Siepmann F et al. Porous pellets as drug delivery system. Drug Dev Ind Pharm 2009;35:655–662.
   PubMed Web of Science ®Google Scholar
• Kranz H, Le Brun V, Wagner T. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug. Int J Pharm 2005;299:84–91.
   PubMed Web of Science ®Google Scholar
• Riis T, Bauer-Brandl A, Wagner T, Kranz H. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm 2007;65:78–84.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Gupta P, Briskin J, Cheskin H, Semla S. Sustained-release multiparticulate formlations of Zileuton. I. In vitro and in vivo evaluation. Int J Pharm 1996;143:179–185.
   Google Scholar
• Wesdyk R, Joshi YM,Vincentis JD,Newman AW,Jain NB. Factors affecting differences in film thickness of beads coated in fluidized bed units. Int J Pharm 1993;93:101–109.
   Web of Science ®Google Scholar
• McConnell EL, Macfarlane CB, Basit AW. An observational study on the influence of solvent composition on the architecture of drug-layered pellets. Int J Pharm 2009;380:67–71.
   PubMed Web of Science ®Google Scholar
• Talukder R, Fassihi R. Gastroretentive delivery systems: hollow beads. Drug Dev Ind Pharm 2004;30:405–412.
   PubMed Web of Science ®Google Scholar
• Vasanthavada M, Wang Y, Haefele T, Lakshman JP, Mone M, Tong W et al. Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation. J Pharm Sci 2011;100:1923–1934.
   PubMed Web of Science ®Google Scholar
• Kowalski J. (2008). Novel opportunities for solid oral dosage form development using a twin screw extruder. In: American Association of Pharmaceutical Scientist Annual Meeting. Atlanta, GA, USA.
   Google Scholar
• Kwan H, Liebowitz S. (1994). Stable extended release oral dosage composition comprising loratidine and pseudoephedrine. United States, 2009, US Patent 5314697.
   Google Scholar
• Bova J, DunneJ. Combinations of HMG-COA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a at night, 2009, Publication No: WO/1999/006046
   Google Scholar
• Charlton ST, Nicholson SJ. A novel immediate release active film coat formulation for use with an extended release gel matrix tablet core. J Pharm Pharmacol 2010;62:1397–1398.
   Google Scholar
• Lipper RD, Desai D,Kiang S. (2006). Case Study: Implementation of Design Space. In: Real World Applications of PAT and QbD in Drug Process Development and Approval. Arlington, Virginia, USA.
   Google Scholar
• Desai D, Rao V, Guo H, Li D, Stein D, Hu FY et al. An active film-coating approach to enhance chemical stability of a potent drug molecule. Pharm Dev Technol 2010;11:1–9.
   Google Scholar
• Carstensen JT, Koff A, Johnson JB, Rubin SH. Tablet-to-tablet variation of drug content of sugar-coated tablets containing drug in the sugar coat. J Pharm Sci 1970;59:553–555.
   PubMed Web of Science ®Google Scholar
• Chen W, Chang SY, Kiang S, Marchut A, Lyngberg O, Wang J et al. Modeling of pan coating processes: prediction of tablet content uniformity and determination of critical process parameters. J Pharm Sci 2010;99:3213–3225.
   PubMed Web of Science ®Google Scholar
• Hagrasy AE, Chang SY, Desai D, Kiang S. Application of Raman Spectroscopy for quantitative in-line monitoring of tablet coating. Am Pharmaceut Rev 2006;9:40–45.
   Google Scholar
• Hagrasy AE, Chang SY, Desai D, Kiang S. Raman Spectroscopy for the determination of coating uniformity of tablets: assessment of product quality and coating pan mixing efficiency during scale-up. J Pharmaceut Innovat 2006;1:37–42.
   Google Scholar
• Chen W, ChangSY, Kiang S, Early W, Paruchuri S, Desai D. The measurement of spray quality for pan coating processes. J Pharmaceut Innovat 2008;3:1872–1875.
   Google Scholar
• Fichana D, Marchut AJ, Ohlsson PH, Chang SY, Lyngberg O, Dougherty J et al. Experimental and model-based approaches to studying mixing in coating pans. Pharm Dev Technol 2009; 14:173–184.
   PubMed Web of Science ®Google Scholar
• Gohel MC, Jogani PD. A review of co-processed directly compressible excipients. J Pharm Pharm Sci 2005;8:76–93.
   PubMed Web of Science ®Google Scholar
• Mohammed GA, Puri V, Bansal AK. Coprocessing of nevirapine and stavudine by spray drying. Pharm Dev Technol 2008;13:299–310.
   PubMed Web of Science ®Google Scholar
• Sadek H, Dietel GL. Film-enrobed unitary-core medicament and the like. U.S. Patent 5,146,730. Editor 1992.
   Google Scholar
• Li Y, Clarke AJ. (2009). A novel liquid dispensing technology for manufacturing low dose immediate release tablets. In: 2009 AAPS Annual meeting.
   Google Scholar